Pure Global AI
NCT06155500Not yet recruiting

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

Novartis PharmaceuticalsClinicalTrials.govother
Verified
Study focus
Disease/Condition
Sickle Cell Disease
Drug/Device/Intervention
OTQ923
Study type
Observational
Intervention type
other
Sponsor & location
Primary sponsor
Novartis Pharmaceuticals
Funder
Novartis
Timeline & enrollment
Phase
N/A
Start date
Nov 27, 2023
End date
Jul 25, 2025
Enrollment
5 participants
Primary outcome

Number of participants with delayed adverse events that are suspected to be related to previous OTQ923 therapy

Summary

CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled
 patients who have received treatment with OTQ923 for long-term safety and efficacy.

ICD-10 classifications
Sickle-cell disordersOther sickle-cell disordersSickle-cell traitSickle-cell anaemia with crisisSickle-cell anaemia without crisis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155500
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06155500 through Pure Global AI's free database. This phase not specified trial is sponsored by Novartis Pharmaceuticals and is currently Not yet recruiting. The study focuses on Sickle Cell Disease. Target enrollment is 5 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.